Disease overview Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an
incidence of 1‐2 cases per 100 000 adults. It accounts for approximately 15% of newly …

Chronic myeloid leukemia (CML) is a hematological cancer, characterized by a reciprocal
chromosomal translocation between chromosomes 9 and 22 [t (9; 22)], producing the Bcr …

The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free
remission (TFR; ie, the ability to maintain a molecular response after stopping therapy) …

BACKGROUND Several studies have demonstrated that approximately one‐half of patients
with chronic myeloid leukemia (CML) who receive treatment with tyrosine kinase inhibitors …

The purpose of this trial was to evaluate the efficacy of 2-year consolidation therapy with
nilotinib, at a dose of 300 mg twice daily, for achieving treatment-free remission in chronic …

Chronic myeloid leukemia (CML) is the best example of successful targeted therapy. Today,
the overall survival of patients with CML treated by using tyrosine kinase inhibitors (TKIs) is …

The objective of this prospective clinical trial (JALSG-STIM213, UMIN000011971) was to
evaluate treatment-free remission (TFR) rates after discontinuation of imatinib in chronic …

1St James's University Hospital, Leeds, 2Imperial College, London, 3University of
Southampton, Southampton, 4University Hospital, Nottingham, 5University Hospital of …

BACKGROUND Dasatinib is a potent BCR‐ABL1 and Src family tyrosine kinase inhibitor. It
is approved at a dose of 100 mg orally daily for the treatment of chronic myeloid leukemia in …

Purpose Preclinical evidence indicates that the bone marrow microenvironment provides a
protective niche for leukemic stem cells, allowing them to evade the effects of BCR-ABL …